Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Lack of enrollment

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: HCQ

Sponsor

Abramson Cancer Center at Penn Medicine